A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

ID Number 16-0116

Principal Investigator(s)
Lewis R Silverman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of the study is to evaluate the efficacy and safety of the experimental study drug imetelstat for the treatment of subjects with myelodysplastic syndrome.  An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA).


Imetelstat has been used in approximately 400 subjects worldwide in studies of different illnesses, including myelodysplastic syndrome.  Imetelstat is a telomerase inhibitor.  Imetelstat blocks an enzyme (a type of protein) involved in the increase in the number of cancer cells.  Blocking this enzyme may be an important mechanism in killing cancer cells.  In this study, imetelstat is tested to see how useful it is in patients with myelodysplastic syndrome.

Contact Information
Rosalie Odchimar
(212) 824-7309

Recruiting Patients: Yes